Significant biosimilar activities this week include: 28 Oct 22 | Health Canada approves additional COVID-19 indication for Actemra® IV (tocilizumab) Roche Canada announced that...
Significant biosimilar activities this week include: 21 Oct 22 | US | Spectrum Pharmaceuticals launched Rolvedon™ Spectrum Pharmaceuticals announced the US launch of Rolvedon™...
Significant biosimilar activities this week include: 14 Oct 22 | BioFactura’s biosimilar ustekinumab shows comparable PK to Stelara® in Ph I trial BioFactura has announced...
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 3) [2022] FCA 1189 Date:Court:Judge:6 October 2022Federal Court of AustraliaRofe...
We are thrilled to announce that Pearce IP’s founder Naomi Pearce, Executive Lawyer, Patent Attorney and Trade Mark Attorney has been recognised by WIPR as a Diversity Champion...
Significant biosimilar activities this week include: 08 Oct 22 | US | Samsung to pursue adalimumab interchangeability in the US In an interview with Managed Healthcare, Samsung...
We are excited to announce that Pearce IP is a finalist in the Lawyers Weekly Women in Law Awards in the category of 2022 Boutique Diversity firm of the Year. The Women in Law...
Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2) [2022] FCA 369Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022]...
Significant biosimilar activities this week include: 30 Sep 22 | EU | EMA accepts Biogen tocilizumab MAA Biogen announced that the EMA has accepted the MAA for BIIB800...
Sanofi v Amgen Inc. [2022] APO 67Date:Venue:Delegate:26 September 2022Australian Patent OfficeSophina CalanniBackground The five patent applications the subject of these...
PiPCast™ | Expedited Patent Prosecution in Australia and New Zealand
The Australian High Court will have an experienced intellectual property judge on its bench, with the appointment of Justice Jayne Jagot to the bench announced on Thursday 29...
Significant biosimilar activities this week include: 22 Sep 22 | CH | STADA launches Alvotech’s Hukyndra® (100mg/mL adalimumab) in Switzerland Alvotech and STADA announced the...
Pearce IP is very proud to announce that its CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been honoured as the 2022 Patent Lawyer of the...
Significant biosimilar activities this week include: 07 Sep 22 | Celltrion’s ustekinumab biosimilar Ph III trials Yonhap News Agency reported that Celltrion’s ustekinumab...
In this PiPCast®, Naomi Pearce walks through the key IP strategies biosimilars companies are using to enable market entry globally, and canvas biosimilar litigation in Australian courts. They also discuss recent litigation settlement activity and lessons learnt.
Significant biosimilar activities this week include: 25 Aug 22 | JP | Lupin and I’rom sign licence for denosumab in Japan Lupin announced that it has entered into an exclusive...
Significant biosimilar activities this week include: 12 Aug 22 | US | Alvotech, Mylan & others file amicus curiae briefs in support of Teva’s skinny label case Alvotech,...
In this PiPCast™, we discuss whether a patent inventor must be human or can include artificial intelligence systems in Australia, and look to the future legal developments in this space.
Significant biosimilar activities this week include: 23 Aug 22 | Amgen announces the results of Ph III eculizumab trials Amgen announced the results of a Ph III study evaluating...
Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2022] HCA 29Date:Court:Judges:17 June 2022High Court of AustraliaKiefel CJ, Gageler, Keane, Gordon, Edelman...
Even the High Court of Australia could not come to a majority decision on the thorny question of the patentability of computer-implemented inventions in its highly anticipated...
Significant biosimilar activities this week include: 11 Aug 22 | ALX Oncology initiates Ph II trials of evorpacept in combination with cetuximab and pembrolizumab ALX Oncology...
Significant biosimilar activities this week include: 27 Jul 22 | CN | Ph III trial shows Qila’s denosumab biosimilar improves bone mineral density It has been reported that a Ph...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
